These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 15290121)

  • 1. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.
    Verel I; Visser GW; Vosjan MJ; Finn R; Boellaard R; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1645-52. PubMed ID: 15290121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
    Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
    J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
    Verel I; Visser GW; Boerman OC; van Eerd JE; Finn R; Boellaard R; Vosjan MJ; Stigter-van Walsum M; Snow GB; van Dongen GA
    Cancer Biother Radiopharm; 2003 Aug; 18(4):655-61. PubMed ID: 14503961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
    Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
    J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
    Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
    J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.
    Fortin MA; Salnikov AV; Nestor M; Heldin NE; Rubin K; Lundqvist H
    Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1376-87. PubMed ID: 17277931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice.
    van Gog FB; Brakenhoff RH; Snow GB; van Dongen GA
    Cancer Immunol Immunother; 1997 Apr; 44(2):103-11. PubMed ID: 9177472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients.
    de Bree R; Roos JC; Plaizier MA; Quak JJ; van Kamp GJ; den Hollander W; Snow GB; van Dongen GA
    Br J Cancer; 1997; 75(7):1049-60. PubMed ID: 9083342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
    Gerretsen M; Schrijvers AH; van Walsum M; Braakhuis BJ; Quak JJ; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1992 Sep; 66(3):496-502. PubMed ID: 1520586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.
    Visser GW; Klok RP; Gebbinck JW; ter Linden T; van Dongen GA; Molthoff CF
    J Nucl Med; 2001 Mar; 42(3):509-19. PubMed ID: 11337531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.
    Tijink BM; Perk LR; Budde M; Stigter-van Walsum M; Visser GW; Kloet RW; Dinkelborg LM; Leemans CR; Neri D; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1235-44. PubMed ID: 19259661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
    Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
    J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.
    Nestor M; Persson M; van Dongen GA; Jensen HJ; Lundqvist H; Anniko M; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1296-304. PubMed ID: 16028065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
    Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
    Perk LR; Vosjan MJ; Visser GW; Budde M; Jurek P; Kiefer GE; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):250-9. PubMed ID: 19763566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
    Börjesson PK; Jauw YW; Boellaard R; de Bree R; Comans EF; Roos JC; Castelijns JA; Vosjan MJ; Kummer JA; Leemans CR; Lammertsma AA; van Dongen GA
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2133-40. PubMed ID: 16609026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions.
    van Gog FB; Visser GW; Stroomer JW; Roos JC; Snow GB; van Dongen GA
    Cancer; 1997 Dec; 80(12 Suppl):2360-70. PubMed ID: 9406684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography.
    Perk LR; Visser OJ; Stigter-van Walsum M; Vosjan MJ; Visser GW; Zijlstra JM; Huijgens PC; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1337-45. PubMed ID: 16832633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody.
    Andratschke M; Gildehaus FJ; Johannson V; Schmitt B; Mack B; Reisbach G; Lang S; Lindhofer H; Zeidler R; Wollenberg B; Luebbers CW
    Anticancer Res; 2007; 27(1A):431-6. PubMed ID: 17352264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.